- Home
- TNXP vs CLYM Comparison
TNXP vs CLYM Comparison
Compare TNXP & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- CLYM
- Stock Information
- Founded
- TNXP 2007
- CLYM 2018
- Country
- TNXP United States
- CLYM United States
- Employees
- TNXP N/A
- CLYM N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- TNXP Health Care
- CLYM
- Exchange
- TNXP Nasdaq
- CLYM NYSE
- Market Cap
- TNXP 116.9M
- CLYM 101.6M
- IPO Year
- TNXP N/A
- CLYM 2021
- Fundamental
- Price
- TNXP $15.71
- CLYM $1.26
- Analyst Decision
- TNXP Strong Buy
- CLYM
- Analyst Count
- TNXP 2
- CLYM 0
- Target Price
- TNXP $585.00
- CLYM N/A
- AVG Volume (30 Days)
- TNXP 1.5M
- CLYM 170.7K
- Earning Date
- TNXP 05-12-2025
- CLYM 05-14-2025
- Dividend Yield
- TNXP N/A
- CLYM N/A
- EPS Growth
- TNXP N/A
- CLYM N/A
- EPS
- TNXP N/A
- CLYM N/A
- Revenue
- TNXP $10,094,000.00
- CLYM N/A
- Revenue This Year
- TNXP $12.17
- CLYM N/A
- Revenue Next Year
- TNXP $789.15
- CLYM N/A
- P/E Ratio
- TNXP N/A
- CLYM N/A
- Revenue Growth
- TNXP 29.94
- CLYM N/A
- 52 Week Low
- TNXP $6.76
- CLYM $1.05
- 52 Week High
- TNXP $672.00
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- TNXP 44.80
- CLYM N/A
- Support Level
- TNXP $15.23
- CLYM N/A
- Resistance Level
- TNXP $22.25
- CLYM N/A
- Average True Range (ATR)
- TNXP 2.36
- CLYM 0.00
- MACD
- TNXP -0.54
- CLYM 0.00
- Stochastic Oscillator
- TNXP 16.54
- CLYM 0.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.